Roche after CHF 30.4bn in H1 sales, with Novartis as the foil

Novartis set the pace, Roche had to answer

The Swiss pharma tape has been doing what it usually does in earnings season, rewarding the names that can show volume, margin, and guidance discipline in the same breath. Novartis did that on July 21, with core operating profit of $5.94 billion and a forecast left intact, although the market trimmed some of the first pop once the one-off help in the quarter was understood. Roche had to answer against that backdrop, and it did so with a first-half print that was solid rather than flashy, which is often the more useful category in this part of the market.

Roche Holding AG (Roche) reported group sales of CHF 30.4 billion for the first half of 2026, up 6% at constant exchange rates but down 2% in Swiss francs because the currency kept biting reported numbers. Core operating profit rose 10% at CER to CHF 11.9 billion, the core operating margin expanded 1.7 percentage points, and core EPS increased 9% at CER to CHF 10.85. The company also reaffirmed full-year 2026 guidance for mid-single-digit sales growth and high-single-digit core EPS growth at CER. That is the kind of print that keeps a large-cap healthcare name in the conversation without forcing a rerating on its own.

Roche versus Novartis, the Swiss split-screen

The comparison with Novartis matters because the two names sit in the same broad defensive bucket, but they do not trade on the same operating mix. Novartis has been leaning on a cleaner growth narrative and a quarter that beat expectations, while Roche is carrying a heavier diagnostics franchise alongside pharmaceuticals and a currency translation burden that shows up immediately in Swiss francs. If you want the short version, Novartis gave the market a cleaner headline, Roche gave it a sturdier base.

That difference shows up in the numbers. Roche’s pharmaceuticals division grew 6% at CER to CHF 23.6 billion, while diagnostics rose 3% at CER to CHF 6.7 billion, or 6% excluding China pricing reforms. The company is still getting the benefit of innovative medicines momentum, and the diagnostics arm is not dead weight, but it is also not the kind of engine that makes a stock rerate by itself. Novartis, by contrast, is still being judged more directly on pipeline and product mix, which is why its quarter drew a sharper market reaction even after the initial move faded.

Roche’s share price reflected that steadier profile. On July 24, ROG.SW traded at 350.30 CHF, up 0.23% or 0.80 CHF from the prior session. That is not a dramatic move, and it does not need to be. In a sector where investors are still sorting through patent cliffs, pricing pressure, and the next round of pipeline readouts, a large-cap Swiss name that can hold guidance and keep margins moving is doing enough to stay relevant. Novartis may have had the cleaner beat, but Roche is the one with the broader operating base.

What the first-half print says about the business mix

Roche’s pharmaceuticals division did the heavy lifting. CHF 23.6 billion in sales at CER growth of 6% tells you the core drug franchise is still carrying the group, and the margin expansion tells you management is not buying growth at the expense of profitability. Core operating profit rising 10% at CER against 6% sales growth is the kind of spread that matters. It says the business is not just growing, it is converting that growth into earnings at a better rate than revenue alone would suggest.

Diagnostics deserves a separate read because it is where the company’s mix can look less straightforward. CHF 6.7 billion in sales, up 3% at CER, is respectable in isolation. The 6% growth rate excluding China pricing reforms is the more revealing figure, because it shows the underlying business is stronger than the reported line suggests. That matters in a year when investors are already sensitive to pricing pressure and regional distortions. Roche does not need diagnostics to be the star every quarter, but it does need it to avoid becoming a drag. This quarter, it did that.

The currency line is the part that should keep your expectations grounded. Sales were down 2% in Swiss francs even as they rose 6% at CER. That gap is not cosmetic. For a Swiss exporter, it is the difference between a clean headline and a more complicated one. Roche cannot control the franc, and the market knows it. What it can control is whether the underlying business keeps compounding through the translation noise. On that score, the first half was good enough.

The insider file is quiet, and that matters in its own way

There is no fresh insider trade to hang a drama on here, and that is the point. The most recent transactions date to March 2026, and no insider trading activity has occurred in the last three months. In a name this large, that is not unusual. Roche is not a small-cap where a single director buy can dominate the tape. It is a mega-cap healthcare group with a deep institutional base and a governance profile that tends to produce fewer headline-grabbing filings.

Our data does still give you a useful comparison point, even if it is a quiet one. The historical T+90 cohort return for the relevant role-and-size bucket is 12.5% (STOXX Europe 600 on the same dates: 9.3%), and that is historical cohort data, not a forecast. Read it as context, not as a promise. In a name like Roche, the absence of recent insider activity does not tell you the business is broken or the stock is cheap. It tells you the filing record is not adding a fresh layer of conviction on top of the operating print.

That is where the comparison with Novartis helps again. Novartis has had the cleaner near-term earnings reaction, Roche has had the steadier operating base, and neither name is being driven by a burst of insider buying. If you are looking for a management signal, you are not getting one from the filing record right now. You are getting it from the guidance reaffirmation and the margin expansion.

Scale versus rerating, and why Roche still looks different

Roche’s scale is the reason the stock can absorb a quarter like this without needing a new story every time. CHF 30.4 billion in half-year sales is a large base, and the company is still growing off it. That matters because the market usually gives large-cap pharma two chances, first to prove the business is stable, then to prove it can still grow. Roche cleared the first test and passed the second well enough to keep guidance unchanged.

Novartis is the more obvious rerating candidate when the market wants a cleaner growth narrative. Roche is the more durable operating story when the market wants evidence that a broad franchise can keep compounding through currency pressure and regional noise. The difference is subtle, but it is real. Roche’s diagnostics arm gives it more breadth, its pharmaceuticals division gives it the earnings engine, and the combination makes the stock less dependent on any single product cycle than some peers. That is one reason analysts often treat Roche as a slower erosion story rather than a binary pipeline bet.

The external backdrop supports that reading. The broader pharma sector has been firm, with U.S. pharma stocks up about 1.6% over the past week and the industry up 40% over the trailing 12 months, according to the sector data in hand. That does not mean every large-cap European name should trade the same way, but it does tell you the market is still willing to pay for defensive earnings visibility when the numbers cooperate. Roche’s first half cooperated.

Where the comparison breaks, and where it does not

The comparison with Novartis breaks if you try to force a single verdict out of two different businesses. Novartis is being judged on a more concentrated growth and pipeline story, and its quarter had enough one-off support that analysts immediately started looking at the second half. Roche is being judged on a broader mix, with pharmaceuticals, diagnostics, and currency translation all pulling on the same report. That makes the headline less explosive, but it also makes the base case less fragile.

The comparison holds if you focus on execution. Both companies are operating in the same sector backdrop, with pricing pressure, patent cliffs, and pipeline scrutiny still in the frame. Both are large enough that the market cares more about consistency than surprise. Both have to show that growth is not just a one-quarter event. Roche’s answer was a reaffirmed outlook and margin expansion. Novartis’s answer was a beat and a hold. Different shapes, same requirement.

That is why the insider record matters only at the margin here. A fresh cluster of buys would have sharpened the debate. A wave of selling would have complicated it. Instead, the file is quiet. So the stock has to stand on the operating print and the peer comparison. That is not a bad place for Roche to be after a half-year report that showed 6% CER sales growth, 10% CER core profit growth, and a guidance reaffirmation.

What to watch before the next Swiss pharma checkpoint

The next checkpoint is not about whether Roche can produce another headline. It is about whether the company can keep the same shape to the numbers when the market has had time to digest the first-half print. Watch pharmaceuticals first, because that is still the main engine. Watch diagnostics second, because the China pricing adjustment can keep distorting the reported line even when the underlying business is healthier than it looks. And watch the franc, because the currency gap between CER and reported Swiss-franc results is still doing real work.

Novartis will remain the cleaner peer reference point for the market, especially if it keeps delivering quarters that beat and hold. Roche, though, has a different kind of resilience. It does not need a perfect quarter to stay in favor. It needs the same thing it delivered here, sales growth at CER, margin expansion, and no sign that the core franchise is losing traction. The first half gave it that.

The insider file will matter again only if it changes. Right now, it does not. No insider trading activity in the last three months, most recent transactions in March 2026, and no fresh filing to argue over. That leaves you with the business, the guidance, and the peer frame. Roche has enough of the first two to stay in the conversation, and Novartis will keep setting the bar for how clean a Swiss pharma quarter can look when the market is in a mood to reward it.

Sources and the July 2026 print

Roche’s half-year results and guidance reaffirmation came from the company’s July 23 update and related earnings coverage. The share price reference is from July 24 trading data. The insider record comes from the company-level insider screen showing no activity in the last three months and the most recent transactions in March 2026.

The peer frame comes from Novartis’s July 21 quarter, where core operating profit came in at $5.94 billion and guidance stayed intact, plus sector context on recent pharma performance and the broader backdrop for Swiss exporters. That is the comparison that matters here, because Roche is not being read in a vacuum. It is being read against a peer that just gave the market a cleaner headline.

The result is a familiar Roche setup. Big base, decent growth, currency drag, no fresh insider signal, and a stock that still has to prove it can turn a solid half into a better rerating later in the year.

This is not investment advice.

This is not investment advice.